Belantamab Mafodotin
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 228 publications
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Journal: Expert opinion on biological therapy
Published: March 17, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 06, 2026
Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies.
Journal: Frontiers in oncology
Published: November 28, 2025
Salvage Therapies After Anti-BCMA CAR-T Failure in Patients With Multiple Myeloma: A Meta-Analysis of Response Rates.
Journal: European journal of haematology
Published: November 10, 2025
Belantamab mafodotin for the treatment of multiple myeloma.
Journal: Expert opinion on biological therapy
Published: October 15, 2025
Mechanism of uptake and toxicity of a BCMA antibody drug conjugate with a MMAF payload by nonantigen expressing cells.
Journal: Cell biology and toxicology
Published: October 10, 2025
Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma.
Journal: International journal of hematology
Published: September 28, 2025
SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 24, 2025
Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.
Journal: British journal of cancer
Published: September 19, 2025
Last Updated: 04/28/2026